Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and…
Pharmaceuticals, Biotechnology and Life Sciences
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and…
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product…
– First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers – FMC-376 is a first-in-class direct…
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access…
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation…
BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) — Bright Green…
Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February…
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent…
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signalsEncouraging early results from the VAXINIA (CF33)…
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host…